fda drug safety communication semaglutide naion 2025 The sent a warning letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know Ophthalmic complications with semaglutide and

Bottom line Insurance coverage for weight loss medication is changing, and the number of states offering Medicaid coverage for weight loss drugs has grown over the past few years

May your reconstitutions stay clear, your concentrations stay accurate, and your protocols stay consistent.

If your doctor orders blood work while you are on semaglutide, tell them you are taking creatine

May is not prone to hypoglycemia as some insulin therapies are

FDA has issued a warning letter to Hims & Hers Health (NYSE:HIMS) over its marketing of compounded semaglutide, the weight loss drug marketed under the brand name Wegovy by Novo Nordisk (NVO)

Supplementation is strongly recommended for plant-based eaters on GLP-1 medications